22:51 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Conformist nanobodies

A University of Zurich team in collaboration with Roche has figured out how to make fully synthetic nanobodies that can bind to membrane proteins in specific conformations -- simultaneously opening up new target space for...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Oct 20, 2016 |  BC Innovations  |  Translation in Brief

Viking’s heart bypass

Viking Therapeutics Inc. (NASDAQ:VKTX) has presented data showing its preclinical thyroid hormone receptor β agonist, VK0214 , cut down pathogenic accumulation of very long chain fatty acids (VLCFAs) in a mouse model of X-linked adrenoleukodystrophy...
00:50 , Mar 27, 2015 |  BC Extra  |  Financial News

Cerenis raises EUR 53.4M in Euronext IPO

Cardiovascular play Cerenis Therapeutics S.A. (Euronext:CEREN) raised EUR 53.4 million ($57.7 million) through the sale of 4.2 million shares at EUR 12.70 in an IPO on Euronext. The IPO price values Cerenis at EUR 225.9...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

Cerenis HDL regulatory update

Cerenis said the European Commission granted Orphan Drug designation to CER-001 to treat apolipoprotein A-1 (APOA1) and ATP-binding cassette transporter 1 ( ABCA1 ) deficiencies. The company said inherited defects in the APOA1 or ABCA1...
07:00 , Aug 21, 2014 |  BC Innovations  |  Targets & Mechanisms

Corneal perspectives

Two independent findings could increase the availability of tissue for corneal transplants. A University of California, San Diego -led team has created a new source of limbal stem cells-which are needed for clear vision-by expressing...
07:00 , Apr 21, 2014 |  BioCentury  |  Emerging Company Profile

Minoryx: Mediating rare metabolism

Minoryx Therapeutics S.L. has two complementary strategies for developing therapies to treat inherited metabolic diseases involving enzyme deficiencies: identifying small molecule chaperones that can restore mutant enzyme function, and repurposing existing drugs to treat the...
07:00 , Jul 30, 2012 |  BioCentury  |  Finance

Blue skies for bluebird

Blue skies for bluebird...
07:00 , Aug 2, 2010 |  BC Week In Review  |  Clinical News

LIM-0705: Phase Ib data

In a double-blind, placebo-controlled, Australian Phase Ib trial in 44 healthy volunteers, tacrolimus plus placebo produced significant perturbations in glucose metabolism and kidney function, while tacrolimus plus oral LIM-0705 attenuated the effects. Both doses of...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Clinical News

LIM-0705: Phase Ia data

In the multiple-ascending dose portion of a Phase Ia trial in 28 healthy volunteers, LIM-0705 significantly reduced the tissue distribution of tacrolimus compared to tacrolimus alone (p<0.001). There were no serious adverse events. Patients received...